title: Temsirolimus therapy in a patient with lung adenocarcinoma harboring an FBXW7 mutation.
abstract: We report the identification of an FBXW7 mutation in a patient with adenocarcinoma of the lung, whose tumor had previously been shown to be EGFR and ALK wild type and who had previously progressed on multiple lines of systemic therapy. She experienced both clinical and radiographic benefit from treatment with the mTOR inhibitor temsirolimus.
authors.affiliation: University of Pittsburgh Cancer Institute, University of Pittsburgh, School of Medicine/Hematology-Oncology, Lung and Thoracic Malignancies Program, Pittsburgh, PA 15232, United States. Electronic address: VillaruzL@upmc.edu.
authors.forename: Liza C
authors.initials: LC
authors.lastname: Villaruz
authors.affiliation: University of Pittsburgh Cancer Institute, University of Pittsburgh, School of Medicine/Hematology-Oncology, Lung and Thoracic Malignancies Program, Pittsburgh, PA 15232, United States.
authors.forename: Mark A
authors.initials: MA
authors.lastname: Socinski
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000235:genetics / Q000532:radiotherapy; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage / Q000009:adverse effects; D018797:Cell Cycle Proteins / Q000235:genetics / Q000378:metabolism*; D019008:Drug Resistance, Neoplasm; D044783:F-Box Proteins / Q000235:genetics / Q000378:metabolism*; D000073979:F-Box-WD Repeat-Containing Protein 7; D005260:Female; D005971:Glutamates / Q000008:administration & dosage / Q000009:adverse effects; D006147:Guanine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D059014:High-Throughput Nucleotide Sequencing; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000532:radiotherapy; D008875:Middle Aged; D058990:Molecular Targeted Therapy; D009043:Motor Activity / Q000187:drug effects; D009154:Mutation / Q000235:genetics; D009362:Neoplasm Metastasis; D000068437:Pemetrexed; D012008:Recurrence; D012074:Remission Induction; D020123:Sirolimus / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D058570:TOR Serine-Threonine Kinases / Q000378:metabolism; D044767:Ubiquitin-Protein Ligases / Q000235:genetics / Q000378:metabolism*; D015430:Weight Gain / Q000187:drug effects
chemical_list: D018797:Cell Cycle Proteins; D044783:F-Box Proteins; D000073979:F-Box-WD Repeat-Containing Protein 7; C513273:FBXW7 protein, human; D005971:Glutamates; D000068437:Pemetrexed; D006147:Guanine; C401859:temsirolimus; D016190:Carboplatin; D044767:Ubiquitin-Protein Ligases; D058570:TOR Serine-Threonine Kinases; D020123:Sirolimus
keywords: FBXW7 mutation; Lung adenocarcinoma; Next generation sequencing; Temsirolimus; mTOR inhibitor